What Happens to DHEA-S Levels in Menopause?

What Happens to DHEA-S Levels in Menopause?

DHEA-S (dehydroepiandrosterone sulfate) declines significantly before and during menopause — most women lose 50–80% of their peak levels by their mid-50s. This drop is driven primarily by adrenal aging, not ovarian failure, which means it happens independently of estrogen loss. Women with already-low adrenal reserve feel it earliest and hardest.

---

The Adrenal Hormone Decline Nobody Talks About

Estrogen and progesterone get most of the attention in menopause conversations, but DHEA-S is the body's most abundant circulating steroid hormone — and it peaks in your mid-20s, then falls at roughly 2–3% per year afterward (Orentreich et al., Journal of Clinical Endocrinology & Metabolism 1984; PMID: 6699602). By the time a woman reaches her early 50s, her DHEA-S concentration may be one-quarter of what it was at its peak.

Unlike estradiol, which drops sharply around the final menstrual period, DHEA-S declines in a slow, predictable arc — a process called adrenopause. This means perimenopausal women are often already significantly depleted before menopause is formally confirmed. If you're wondering what happens to estradiol in perimenopause, it's worth knowing that the two declines overlap but are mechanistically separate: estradiol loss is primarily ovarian, while DHEA-S loss is primarily adrenal.

The adrenal cortex produces DHEA, which is rapidly sulfated in the bloodstream to DHEA-S. Both the zona reticularis (the innermost adrenal layer) and, to a lesser extent, the ovaries contribute. As ovarian function winds down, any ovarian contribution to DHEA-S is also lost — compounding the adrenal decline that was already underway.

---

Why DHEA-S Matters Beyond Estrogen

DHEA-S itself is biologically inactive — it's a reservoir molecule. Once it enters peripheral tissues (skin, brain, bone, adipose, immune cells), local enzymes convert it into active androgens and estrogens. This means postmenopausal women who have lost most circulating estradiol still rely on DHEA-S-derived estrogens in target tissues for bone protection, skin integrity, cognitive function, and libido. When DHEA-S is also low, that local conversion pathway essentially runs dry.

Clinically, this matters for several overlapping reasons:

• Bone density: DHEA supplementation in women with low baseline DHEA-S has been associated with modest improvements in lumbar spine bone mineral density, particularly when combined with calcium and vitamin D (Jankowski et al., Journal of Clinical Endocrinology & Metabolism 2006; PMID: 16720656).
• Vaginal health: Intravaginal DHEA (prasterone) is FDA-approved specifically because peripheral conversion to local estrogens and androgens restores vaginal epithelium without meaningfully raising systemic estradiol — an important distinction for women who cannot use systemic HRT.
• Cognitive function: DHEA receptors (including sigma-1 receptors) are expressed in hippocampal tissue. Animal models and some human observational data link low DHEA-S to worse verbal memory, though large intervention trials in cognitively intact older adults show modest effects at best (Parsons et al., Psychoneuroendocrinology 2012).
• Immune regulation: DHEA-S exerts anti-inflammatory effects partly by antagonizing cortisol at the glucocorticoid receptor level. A falling DHEA-S:cortisol ratio — common in stressed perimenopausal women — tips the neuroimmune balance toward a pro-inflammatory state.

That last point is worth dwelling on. What is a normal cortisol level in menopause? is a question many women are asking alongside their DHEA-S results, because the two hormones are functionally linked. When DHEA-S falls and cortisol stays elevated — as it often does under chronic stress — the net effect on immune function, sleep, and mood is significantly worse than either change alone.

---

Does DHEA Work? What Clinical Trials Actually Show

This is where the evidence gets genuinely nuanced. DHEA supplementation trials have produced inconsistent results, and the variation is explained almost entirely by baseline DHEA-S levels and the outcome being measured.

The ECHO trial (Kroiss et al., European Journal of Endocrinology 2009) randomized women with adrenal insufficiency to receive DHEA 50 mg/day or placebo for 12 months. Women who started with very low DHEA-S responded with measurable improvements in fatigue, sexual function, and mood. Women with normal baseline levels — almost by definition excluded from this population — showed little additional benefit, reinforcing that DHEA replacement is corrective, not enhancing.

The DHEAge Study (Baulieu et al., Proceedings of the National Academy of Sciences 2000; PMID: 10639127) followed 280 adults aged 60–79 who took DHEA 50 mg/day for 12 months. In women, the study found significant improvements in libido and skin hydration. Bone mineral density increased in women over 70 who had the lowest baseline DHEA-S. No significant effects were seen in men or in younger women with higher baseline values — again pointing to a threshold model.

A Cochrane-style systematic review synthesizing 28 randomized controlled trials (Nair et al., Mayo Clinic Proceedings 2009) concluded that DHEA had a small but consistent benefit on sexual function in menopausal women, a modest benefit on quality of life and mood in women with documented adrenal insufficiency, and negligible effects on most endpoints in healthy adults with age-appropriate DHEA-S levels. The key takeaway: testing first is not optional — it's what determines whether supplementation is appropriate.

On dosing: Most trials use 25–50 mg/day oral DHEA, with some researchers arguing that 25 mg achieves adequate tissue conversion with less androgenic side-effect risk (acne, oily skin, mild hirsutism) than 50 mg. Sublingual and transdermal forms bypass first-pass liver metabolism and may achieve higher DHEA-S conversion at lower doses, though comparative pharmacokinetic data are limited.

---

DHEA-S and Stress: The Cortisol Connection

Chronic psychological stress accelerates the functional impact of declining DHEA-S because it keeps cortisol chronically elevated. Since DHEA and cortisol are both derived from pregnenolone via the adrenal cortex, sustained stress essentially redirects precursor toward cortisol at the expense of DHEA synthesis — a phenomenon sometimes called "pregnenolone steal," though the biochemistry is more nuanced than that term implies.

The practical consequence is that a woman entering perimenopause under high allostatic load may have a DHEA-S:cortisol ratio that looks more like that of a 70-year-old than a 48-year-old. The ratio matters more than either absolute value alone in predicting immune resilience, inflammatory tone, and psychological stress responses (Lennartsson et al., Psychoneuroendocrinology 2013; PMID: 23261529).

Adrenal-supportive strategies that help manage cortisol — including adaptogenic herbs — can indirectly preserve a healthier DHEA-S:cortisol balance. Ashwagandha (KSM-66) at 600 mg/day reduced morning cortisol by approximately 27% in a double-blind RCT of chronically stressed adults (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798). Whether blunting cortisol release also allows slightly higher DHEA synthesis remains an area of active research, but the clinical rationale for managing stress-driven cortisol excess in the perimenopausal window is strong.

For a broader look at how the hormonal environment shifts across the menopausal transition, what happens to TSH levels during menopause is a useful companion read — thyroid function interacts with adrenal output in ways that can amplify DHEA-S-related fatigue and temperature dysregulation.

---

What Your DHEA-S Lab Result Actually Tells You

DHEA-S is the preferred biomarker over DHEA itself because its half-life is 10–20 hours (versus 1–3 hours for DHEA), making it far more stable across the day. A single fasting morning draw is sufficient — no timing precision is required the way cortisol testing demands.

Reference ranges vary significantly by laboratory and age band, which is one of the most common sources of confusion. A result flagged "normal" on a standard adult reference range may represent the very bottom of what's age-appropriate for a 38-year-old, yet still read within range on the lab report.

For context, what is a normal DHEA-S level in menopause and what is a normal DHEA-S level in perimenopause both have dedicated breakdowns of the age-stratified reference intervals and what functional decline looks like relative to chronological age. The short version: most functional medicine practitioners use an optimal range of 150–250 µg/dL for postmenopausal women, versus a laboratory "normal" that may bottom out near 20–30 µg/dL.

When levels are very low (below 70–80 µg/dL postmenopause), it's worth ruling out:

1. Primary adrenal insufficiency (Addison's disease) — rare but serious; check with an AM cortisol and ACTH stimulation test if suspected
2. Hyperprolactinemia — elevated prolactin can suppress adrenal androgen output
3. Chronic glucocorticoid use — exogenous steroids suppress endogenous adrenal DHEA production
4. Severe caloric restriction or disordered eating — adrenal synthesis requires adequate cholesterol substrate

When DHEA-S is unexpectedly high in a postmenopausal woman, the differential includes adrenal hyperplasia, adrenal tumor, or exogenous DHEA supplementation not disclosed at intake. High DHEA-S is not a benign finding in older postmenopausal women and warrants investigation.

---

What This Means for Your Formula

Ones takes DHEA-S seriously as a biomarker — when lab results show documented low DHEA-S in the context of perimenopausal or menopausal transition, the AI practitioner interprets it alongside cortisol ratio, thyroid markers, and lifestyle data before making formula decisions.

For women whose primary driver is the stress-cortisol-adrenal axis suppressing their DHEA-S, the formula may include:

• Ashwagandha KSM-66 at 600 mg — the specific extract and dose used in the Chandrasekhar 2012 RCT showing 27% cortisol reduction. By reducing cortisol excess, this supports a healthier adrenal environment and a more favorable DHEA-S:cortisol ratio.
• Ones Adrenal Support blend — a proprietary system blend formulated to support adrenal resilience. This addresses the upstream manufacturing context of adrenal hormones, not just downstream symptom suppression.
• Rhodiola Rosea — at clinically studied doses, Rhodiola helps moderate HPA axis reactivity, which is relevant when adrenal fatigue and cortisol dysregulation are compounding DHEA-S decline.

Because Ones builds formulas from lab results — not from symptom surveys alone — the distinction between "adrenally depleted with cortisol excess" and "adrenally depleted with low-normal cortisol" produces meaningfully different formulas. That specificity is what separates personalized supplementation from a generic adaptogen stack.

---

Key Takeaways

• DHEA-S declines 50–80% from its mid-20s peak by the time most women reach menopause — this is driven by adrenal aging (adrenopause), not ovarian failure, and it starts long before the final menstrual period.
• DHEA-S is a reservoir molecule: its real function is local conversion to active estrogens and androgens in bone, skin, brain, and vaginal tissue — making its decline consequential even when systemic estradiol is managed with HRT.
• Clinical trials support DHEA supplementation specifically in women with documented low baseline levels — benefits to libido, sexual function, and bone density are meaningful at 25–50 mg/day; effects in women with age-appropriate levels are minimal.
• The DHEA-S:cortisol ratio matters as much as the absolute DHEA-S value — chronic stress accelerates the functional impact of declining DHEA-S by keeping cortisol elevated and competing for shared adrenal precursors.
• Test before you supplement: a single fasting DHEA-S draw is stable and informative; interpret results using age-stratified reference ranges, not generic adult normals.
• Adrenal support through cortisol modulation — using evidence-based adaptogens like KSM-66 ashwagandha at 600 mg/day — is a rational complement to or precursor of direct DHEA supplementation, particularly when the stress axis is clearly dysregulated.